Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
about
MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis.CSF analysis for protein biomarker identification in patients with leptomeningeal metastases from CNS lymphoma.What should be done to minimize pain without any sexual function deterioration in transrectal prostate biopsy?Prostate cancer screening-when to start and how to screen?Impact of United States Preventive Services Task Force recommendations on prostate biopsy characteristics and disease presentation at a tertiary-care medical center
P2860
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
@ast
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
@en
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
@nl
type
label
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
@ast
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
@en
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
@nl
prefLabel
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
@ast
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
@en
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
@nl
P2093
P2860
P1476
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines
@en
P2093
Nathan Lawrentschuk
Shannon McGrath
Sonja Cabarkapa
P2860
P304
P356
10.1016/J.PRNIL.2016.09.002
P407
P577
2016-12-01T00:00:00Z